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Abstract
Background
High serum levels of the pro-inflammatory adipokine resistin have been associated with de-
creased renal function in the general population. The goal of this study was to investigate
whether such association is also present among diabetic subjects, who are at increased
risk of renal function loss.
Methods
The cross-sectional association between serum resistin levels and estimated glomerular fil-
tration rate (eGFR) was investigated in 1,560 type 2 diabetic (T2D) patients of European an-
cestry comprised in two different cohorts: 762 patients from San Giovanni Rotondo (SGR;
Italy) and 798 patients from Boston (US).
Results
Serum resistin was inversely associated with eGFR in SGR [β (SE) for one SD of resistin
increment = -1.01 (0.70) ml/min/1.73m2, p = 0.019] and in Boston [β (SE) = -5.31 (0.74)
ml/min/1.73m2, p< 0.001] samples, as well as in the two studies combined [β (SE) = -3.42
(0.52) ml/min/1.73m2, p< 0.001]. The association was unaffected by adjustment for smok-
ing habits, BMI, waist circumference, diabetes duration, HbA1c, insulin treatment, hyperten-
sion and lipid-lowering therapy: β (SE) for one SD of resistin increment = -1.07 (0.70), p =
0.02; -5.50 (0.88), p< 0.001; and -2.81 (0.55) ml/min/1.73m2, p< .001, in SGR, Boston and
the two studies combined, respectively. The association was significantly stronger in men
than in women (p for resistin-by-gender interaction = 0.003). For each resistin SD incre-
ment, the odds of having eGFR< 0 ml/min/1.73m2 increased by 22% (OR = 1.22; 95% CI
1.02–1.44; p = 0.025) in SGR sample, 69% (OR = 1.69; 95% CI 1.38–2.07; p< 0.001) in
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Boston sample, and 47% (OR = 1.47; 95% CI 1.29–1.68; p< 0.001) in the two studies con-
sidered together. Similar associations were observed in the adjusted model: OR 95% CI for
each SD resistin increment being 1.23 (1.03–1.46), p = 0.021; 1.52 (1.20–1.92), p< 0.001;
1.33 (1.16–1.53), p< 0.001, in SGR, Boston and the two studies combined, respectively.
Conclusions
This is the first report of an association between high serum resistin and low eGFR in pa-
tients with T2D of European ancestry.
Introduction
Chronic kidney disease (CKD), defined as reduced glomerular filtration rate (GFR), is a leading
cause of premature death in patients with type 2 diabetes (T2D) [1–3]. A better understanding
of the pathogenic mechanisms responsible for GFR decline in these patients is urgently needed
to devise new interventions aimed at tackling this problem.
Besides hyperglycemia, many metabolic features of T2D, such as obesity, hypertension, and
dyslipidemia, all clustering in insulin resistance, are known to have deleterious effects on kid-
ney function [4,5]. Chronic low-grade inflammatory—another characteristic features of the di-
abetic state—has also been recognized as an important pathogenetic factor [6,7].
Cytokines secreted by adipose tissue (collectively known as adipokines) have been linked to
both insulin resistance and low-grade inflammation [8]. Among them is resistin—a 12.5 kDa
cysteine-rich protein that in humans is primarily secreted by the macrophages [9,10] embed-
ded in the adipose tissue—which has been implicated in cardiovascular disease and atherogen-
esis [11–13]. Several cross-sectional studies have reported an inverse relationship between
serum resistin levels and kidney function [14–17]. Such association has been described in the
general populations [16] and in selected clinical settings [14,15,17] but not in T2D, for which
only scant data, derived from post-hoc, subgroup analyses, are available [15].
To gain insights into the role of resistin in kidney function in diabetes, we investigated
whether increased resistin levels are associated with low eGFR in more than 1,500 T2D patients
of European ancestry from two different geographical regions.
Subjects and Methods
The San Giovanni Rotondo sample (SGR)
Baseline values of 762 subjects with T2D (defined according to the ADA 2003 criteria) from
Gargano (Southern-Centre Italy) were used for this study. They are part of the Gargano Mor-
tality Study, a cohort of consecutively recruited diabetic patients used for prospective investiga-
tion on determinants of all-cause mortality in T2D. The general features of this study have
been previously described [18,19].
The Boston sample
Baseline values of 798 subjects with T2D (defined according to the ADA 2003 criteria) who
lived in the greater Boston area and received treatment at the Joslin Clinic and/or the Beth Isra-
el Deaconess Medical Center (BIDMC) at the time of their recruitment, were used for this
study. They are part of the Joslin Hearth Study which is a case-control study, comprising
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diabetic patients with (i.e. cases) or without (i.e. controls) coronary artery disease. The general
features of this study have been previously described [19,20].
Data Collection and Definitions
Clinical data were obtained from a standardized interview and examination. Body mass index
(BMI) was calculated by dividing the weight (in kilograms) by squared height (in meters). Hy-
pertension was defined as a systolic blood pressure was> 130 mmHg or diastolic blood pres-
sure was> 85 mmHg or presence of antihypertensive therapy. Smoking habits, dyslipidemia
(as indicated by the presence of lipid-lowering therapy), and insulin treatment were also re-
corded at the time of examination. Data regarding medications were confirmed by review of
medical records. Individuals who reported smoking cigarettes regularly during the year before
the examination were considered current smokers. Diabetes duration was calculated from the
current age and the age at diagnosis of diabetes.
In the SGR sample, blood samples were collected between 8:00 and 9:00 AM after an over-
night fast. In the Boston sample, blood samples were obtained between 7:00 AM and 6:00 PM
without the requirement of fasting. Serum aliquots were stored at -80°C.
Serum creatinine was measured by using the modified kinetic Jaffè reaction. Estimated GFR
was then calculated by using both MDRD and CKD-EPI equations [21,22].
Ethics
The study protocols and the informed consent procedures were approved by the Institutional
Ethic Committee of Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) ‘‘Casa Sollievo
della Sofferenza” and of the Joslin Committee on Human Studies and the Beth Israel Deaconess
Medical Center Committee on Clinical Investigations, respectively. All participants gave writ-
ten informed consent.
Measurement of Circulating Resistin Levels
Serum resistin concentrations were measured by a commercial ELISA (Bio Vendor, Brno
Czech Republic) at the Research Unit of Diabetes and Endocrine Diseases at ‘‘Casa Sollievo
della Sofferenza”, as previously described [23]. Inter—and intra-assay coefficients of variation
were 7.0–8.1% and 5.2–6.6%, respectively.
Statistical Methods
Patients’ baseline characteristics are reported as mean ± standard deviation (SD) and percent-
ages for continuous and categorical variables, respectively.
Baseline comparisons between groups were performed using Pearson χ2 test for categorical
variables, T-test and ANOVA models for normal-distributed continuous variables and Mann-
Whitney U test for skewed-distributed continuous variables.
The association between resistin levels and eGFR (i.e. the dependent variable) as a continu-
ous trait was investigated by multivariate linear regression analysis after logarithm transforma-
tion. Covariates were smoking habits, BMI, waist circumference, diabetes duration, HbA1c,
insulin treatment, hypertension and lipid-lowering therapy, chosen because of their known in-
fluence on GFR. Age was not used as covariate because it is already included in the MDRD for-
mula and also because of its co-linearity with disease duration. Because of the intrinsic nature
of its design (i.e. case-control), analyses of the Boston study were adjusted by coronary artery
disease status (i.e. yes/no, which is 0/1).
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Results were reported as linear model coefficients along with their standard errors [β (SE)].
The association between resistin levels and eGFR as a dichotomous trait (i.e. or<60 ml/
min/1.73m2) was tested by multivariable logistic regression analysis. Results were reported as
Odds Ratios (OR), along with their 95% confidence interval (95% CI).
Random effect meta-analysis was performed in an individual patient data meta-analysis
fashion [24] after checking for heterogeneity (i.e. the presence of a significant exposure-by-
sample interaction).
A p-value 0.05 was considered as significant. All analyses were performed using SPSS v.15
(SPSS, Chicago IL) and SAS Release 9.1.3 (SAS Institute, Cary, NC, USA).
Results
Clinical features of patients of both studies are shown in Table 1 and Table A in S1 File.
The two samples were quite different in terms of most clinical variables (p< 0.05) but, age
and anti-hyperglycemic treatment. Correlations between resistin circulating levels and clinical
features are shown in Table B in S1 File. In both samples, as well as in the combined data,
which were analyzed by random effect individual meta-analysis, because of the presence of het-
erogeneity across samples (p of heterogeneity = 3.310−6), an inverse association was found be-
tween serum resistin and eGFR, considered as a continuous trait: β (SE) for one SD of resistin
increment = -1.01 (0.70), p = 0.019; -5.31 (0.74), p< 0.001 and -3.42 (0.52) ml/min/1.73m2,
p< 0.001, in SGR, Boston and the two studies combined, respectively (Table 2).
Results were essentially the same after adjustments for smoking habits, BMI, waist circum-
ference, diabetes duration, HbA1c, insulin treatment, hypertension and lipid-lowering therapy
in both samples as well as in the combined analysis: β (SE) for one SD of resistin increment =
-1.07 (0.70), p = 0.02; -5.50 (0.88), p< 0.001; and -2.81 (0.55) ml/min/1.73m2, p< 0.001, re-
spectively (Table 2). In this combined analysis, the association between resistin and eGFR was
significantly different across sexes: adjusted β (SE) per one SD of resistin increment being -3.62
(0.76) and -1.62 (0.78) ml/min/1.73m2 in men (n = 909) and in women (n = 651), respectively
(p for resistin-by-sex interaction = 0.003). In this pooled analysis, resistin levels were not differ-
ent in men as compared to women (p = 0.50).
Table 1. Clinical characteristics of patients from SGR and Boston studies.
SGR sample (n = 762) Boston sample (n = 798)
Sex (males %) 388 (50.9) 521 (65.3)
Age (yrs) 62.0±9.6 64.5±6.8
Smokers (%) 173 (22.7) 399 (50.0)
BMI (kg/m2) 30.9±5.5 32.2±5.7
Waist circumference (cm) 102.2±13.5 113.6±13.2
Diabetes duration (yrs) 10.9±9.1 12.8±7.8
HbA1c (%) 8.7±1.9 7.4±1.3
Insulin treatment (%) 318 (41.7) 365 (45.7)
Hypertension (%) 392 (51.4) 596 (74.7)
Lipid-lowering therapy (%) 255 (33.5) 608 (76.2)
Resistin (ng/ml) 10.2±8.2 7.5±5.4
eGFR (ml/min/1.73m2) 74.0±19.8 70.2±21.5
Continuous variables were reported as mean ± SD whereas categorical variables were reported as total
frequency and percentages. SGR: San Giovanni Rotondo; BMI: Body Mass Index; HbA1c: glycated
haemoglobin;, eGFR: estimated glomerular filtration rate.
doi:10.1371/journal.pone.0119529.t001
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Very similar results were obtained in both SGR [adjusted β (SE) = -1.45 (0.63) ml/min/
1.73m2, p = 0.005)] and Boston [adjusted β = -5.37 (0.82) ml/min/1.73m2, p< 0.001)] samples
when CKD-EPI, rather than MDRD, formula was used for measuring eGFR.
In both studies, serum resistin concentrations were significantly higher in patients with
eGFR< 60 ml/min/1.73m2 compared with patients with eGFR 60 ml/min/1.73m2
(p< 0.001); (Table A in S1 File). For each SD increment in resistin levels, the odds of
eGFR< 60 ml/min/1.73m2 increased by 22% (OR = 1.22; 95% CI 1.02–1.44; p = 0.025) in SGR
sample, 69% (OR = 1.69; 95% CI 1.38–2.07; p< 0.001) in Boston sample, and 47% (OR = 1.47;
95% CI 1.29–1.68; p< 0.001) in the two combined samples which were analyzed by random ef-
fect individual meta-analysis, because of the presence of heterogeneity across them (p of het-
erogeneity = 0.014) (Table 3).
These associations were unaffected by adjustment for the same covariates considered above:
OR for each SD resistin increment being 1.23 (1.03–1.46), p = 0.021; 1.52 (1.20–1.92),
p< 0.001 and 1.33 (1.16–1.53), p< 0.001, in SGR, Boston and the two studies combined, re-
spectively (Table 3).
Table 2. Association between serum resistin levels and eGFR (continuous trait).
SGR sample (N = 762) Boston sample (N = 798) Individual data meta-analysis
(1,560)*
β (SE) P β (SE) P β (SE) P
Model 1 -1.01 (0.70) 0.019 -5.31 (0.74) <0.001 -3.42 (0.52) <0.001
Model 2 -1.07 (0.70) 0.02 -5.50 (0.88) <0.001 -2.81 (0.55) <0.001
SGR: San Giovanni Rotondo.
The β linear coefficients represent the change in eGFR level for 1SD increase in resistin. SE: standard error.
Model 1 = unadjusted (Boston sample was adjusted by coronary artery disease status-yes/no).
Model 2 = adjusted by smoking habits, BMI, waist circumference, diabetes duration, HbA1c, insulin treatment, hypertension and lipid-lowering therapy
(Boston sample was adjusted by coronary artery disease status-yes/no).
*Since the effect in SGR was different than that in Boston sample (p for beta values heterogeneity being = 3.3*10−6), individual data meta-analysis was
carried out by using random effects.
doi:10.1371/journal.pone.0119529.t002
Table 3. Association between serum resistin levels and low eGFR (<60ml/min/1.73m2).
SGR sample (N = 762) Boston sample (N = 798) Individual data meta-analysis
(1,560)*
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Model 1 1.22 (1.02–1.44) 0.025 1.69 (1.38–2.07) <0.001 1.47 (1.29–1.68) <0.001
Model 2 1.23 (1.03–1.46) 0.021 1.52 (1.20–1.92) <0.001 1.33 (1.16–1.53) <0.001
SGR: San Giovanni Rotondo;
OR (95% CI) are given for SD increase of resistin levels.
Model 1: unadjusted (Boston sample adjusted by coronary artery disease status-yes/no).
Model 2: adjusted by smoking habits, BMI, waist circumference, diabetes duration, HbA1c, insulin treatment, hypertension and lipid-lowering therapy
(Boston sample adjusted by coronary artery disease status-yes/no).
*Since the effect in SGR was different than that in Boston sample (p for OR values heterogeneity being = 0.014), individual data meta-analysis was
carried out by using random effects
doi:10.1371/journal.pone.0119529.t003
Resistin and Kidney Function in Type 2 Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0119529 March 26, 2015 5 / 9
Discussion
In this study of a large number of T2D patients of European ancestry, we have shown that
resistin levels are inversely related to eGFR and that the proportion of individuals with
eGFR< 60 ml/min/1.73m2 increases significantly with increasing resistin levels. The associa-
tion between resistin and eGFR was observed in two populations from different geographical
regions, supporting a broad generalizability of these data. To the best of our knowledge, our
finding is the first indicating such association among patients with T2D and resembles data so
far obtained in the general population [16] and specific clinical sets as well [14,15,17].
Of note, the association we observed was significantly stronger among men than women. A
similar sexual dimorphism has been previously reported for the association between adiponec-
tin and chronic renal disease [25] or cardiovascular mortality [26]. Whether the sex specific as-
sociation we observed is due to interaction between resistin and either sex-linked genes and/or
sexual hormone effects is not known and deserves future investigations. Nonetheless, while
waiting for further studies in additional samples, our finding definitively suggests the need of
taking into account possible sex specific associations when addressing the role of pro-athero-
genic risk factors; in addition, they point to the need of setting up studies specifically designed
to unravel the different biology underlying renal dysfunction in men and women.
Epidemiological cross-sectional associations can offer only speculation about the biology
underlying them. On one hand we can speculate that, through its pro-inflammatory effect
[27,28], resistin may well be deleterious on kidney function, quite similarly to what is believed
for cardiovascular disease [19,29,30]. On the other hand, although we have previously shown
that serum resistin is inversely associated with eGFR also in relatively young, non diabetic sub-
jects with normal kidney function [17], we cannot exclude that high resistin is simply a conse-
quence of reduced glomerular filtration rate, a hallmark of aged diabetic patients as those we
here studied. Under this scenario, resistin would be an important mediator of the deleterious
effect of reduced kidney function on the risk of cardiovascular disease.
Strengths of our study are the overall sample size, consisting of a total of 1,560 diabetic pa-
tients and the fact that the resistin measurements were centralized. In this context, the observed
difference in serum resistin concentration between the two cross-sectional studies, with Boston
participants having 20–30% lower mean levels as compared to SGR individuals, is somewhat
surprising. One possibility is that such difference was due to the different proportion of pa-
tients treated with lipid lowering agents in the two studies (76% in the Boston sample as com-
pared to 33% in the SGR sample). Such agents are mainly statins, which are known to reduce
resistin concentrations [31,32]. This hypothesis is supported by the observation that partici-
pants in the SGR sample who were on statins treatment had serum resistin levels 10% lower
than patients who were not on statins (data not shown). Another possibility is that in the Bos-
ton sample serum resistin is lower because in some cases it has been measured in non fasting
status, a condition reported to decrease its circulating concentration [33]. At variance, given
that several studies have reported that circulating resistin levels are relatively stable within indi-
viduals over time, we can exclude that the observed difference in serum resistin levels between
SGR and Boston samples is due to the different storage time [34–36]. Regardless of the reasons
for this discrepancy, the fact that the inverse association between resistin and eGFR is fully rep-
licable across the two studies makes our finding especially convincing.
While a previous report have shown that the association between resistin and GFR remains
significant when also C-Reactive Protein (CRP) is taken into account [15], a clear limitation of
our study is the lack of high sensitive CRP measurements in both study samples. Such data
would have allowed speculations on whether or not the association we observed was mediated
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by inflammatory pathways. Also the lack of information on different classes of anti- hyperten-
sive and anti- hyperglycemic drugs has to be recognized as a limitation.
A further limitation is the quite clear differences in baseline clinical features between the
two samples, which may have played the role in determining some heterogeneity in the associa-
tion between resistin and kidney function. Being aware of this limitation, we were conservative
enough to use random-effect meta-analysis, which takes into account any difference across the
two samples. An additional limitation is the very intrinsic nature of our study design, which
lacks a prospective observation. In fact, the Boston sample is a cross-sectional observation,
while the SGR sample has been followed-up but only for all-cause mortality.
In addition, we cannot say whether or not our present finding is generalizable to popula-
tions of different ethnicity with different environmental and/or genetic background, two fac-
tors which are possible modulators of serum resistin levels [37].
In conclusion, our data clearly show that there is an independent association between serum
resistin and GFR among patients with T2D. Further studies are warranted to examine the exact
mechanisms underlying this relationship and to explore the potential role of resistin as a tool
for improving prediction, prevention and treatment strategies aimed at reducing the burden of
kidney function loss in such high risk individuals.
Supporting Information
S1 File. Table A, Clinical characteristics of patients according to eGFR (/<60ml/min/
1.73m2). Table B, Correlation (r values) between serum resistin concentration (ng/ml) and
clinical features.
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